Arestin

OraPharma, Inc., a pharmaceutical company specializing in products for the dental market, was rated as the top company for customer support by a survey of dental health professionals recently conducted by Health Products Research, Inc.® (HPR).

According to James Charnetski, Vice President of Market Research/Health Products Research, "The fact that over three-quarters of the dental offices surveyed cited OraPharma as providing the best level of support to their practice out of companies with an interest in the management of periodontal disease clearly places the organization as the best in its class. A score of 50% is considered a significant accomplishment -- the 76% level demonstrates OraPharma's commitment to providing unsurpassed service and support for its customers."

The extensive blinded research findings were the result of HPR's Metropolitan Area Promotional Audit (MPA). This self-reported diary was completed by 647 randomly selected offices from across the U.S. Offices were queried on their hygiene and periodontal disease treatment protocols as well as the products they use and the companies that support those products.

"We are very proud of the HPR survey result," said Michael Cavanaugh, Executive Director, Marketing. "Our commercial team received very high ratings from dental practitioners, especially pertaining to our account managers' professionalism and our innovative support of dental professionals and their patients."

About OraPharma, Inc.

OraPharma, Inc., is a specialty pharmaceutical company, which discovers, develops, and commercializes therapeutics for oral health. OraPharma is dedicated to the dental community, specifically the periodontal space with its lead product, ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg.

In addition to ARESTIN®, OraPharma also distributes Oraqix® (lidocaine and prilocaine periodontal gel) 2.5% / 2.5%, a new sub-gingival local anesthetic periodontal gel, indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing and is manufactured by Dentsply Pharmaceuticals.

Along with ARESTIN® and Oraqix®, OraPharma also promotes REACH® ACCESS(TM) Daily Flosser, REACH® CLEAN BURST(TM) Dental Floss and ACT® Anticavity Fluoride Rinse, distributed by McNeil-PPC, Inc., to the dental community.

About ARESTIN®

OraPharma's flagship product ARESTIN® is indicated as an adjunct to scaling and/or root planing procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and/or root planing.

ARESTIN® contains minocycline, a tetracycline derivative, and therefore should not be used in children and in pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth.

The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to scaling and/or root planing and scaling and/or root planing + placebo.

About Oraqix®

Oraqix,® manufactured for OraPharma, Inc. by Dentsply Pharmaceuticals, is the first FDA-approved subgingival anesthetic indicated for use in adults requiring anesthesia for scaling and/or root planing procedures. The patient friendly, needle-free application avoids patients concerns about needles and injections. Oraqix® is a trademark of Dentsply Pharmaceuticals.

For more information, visit www.orapharma.com or call 1-866-273-7846.

Contact: Lanmark Group Michael Ventriello mventriello@lanmarkgroup.com www.lanmarkgroup.com